Advertisement


Bradley J. Monk, MD, on Ovarian Cancer: New Data on Rucaparib Monotherapy vs Placebo as Maintenance Treatment

2022 ASCO Annual Meeting

Advertisement

Bradley J. Monk, MD, of the University of Arizona College of Medicine and Creighton University School of Medicine, discusses phase III findings from the ATHENA–MONO (GOG-3020/ENGOT-ov45) trial. It showed that rucaparib as first-line maintenance treatment, following first-line platinum-based chemotherapy, improved progression-free survival in patients with ovarian cancer, irrespective of homologous recombination deficiency status (Abstract LBA5500).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
ATHENA-MONO was a randomized Phase 3 trial looking at rucaparib versus placebo in frontline maintenance after responding to platinum-based therapy. Now you may say, "We already use that." There was another study, which I'm very proud of, called PRIMA that I was the last author on. That study is very helpful and gained FDA approval as you know in April 2020, but this adds confidence to that. In fact, the ASCO guidelines say that all patients with newly diagnosed advanced ovarian cancer who respond to a platinum-based therapy should be considered for a PARP inhibitor. So hopefully if you're not doing it, you'll begin, that ATHENA-MONO will add confidence to it. Now, the medication that we studied was rucaparib. Rucaparib is a PARP inhibitor. It has four doses, 600, 500, 400, 300. The primary endpoint was in patients who had a molecular signature consistent with homologous recombination according to the FoundationOne CDx. When we randomized patients, and they're randomized 4:1, 528 patients in 24 countries in more than 200 sites, we reached our primary endpoint. Think of this. The hazard ratio versus placebo in the rucaparib patients, according to the HRD biomarker, which is about half of the patients based on the investigator, was 28.7 months. Think of that. Newly diagnosed advanced ovarian cancer, stage three and four that respond to platinum-based therapy now can live more than two years versus placebo where they live less than a year, 11.3 months. Based on a step-down analysis, we pivoted to an intent-to-treat analysis and it was still double: placebo, 9.2 months, the rucaparib arm, 20.2 months, hazard ratio of 0.52. Even in the biomarker negative subgroup there was still a statistically significant and clinically relevant impact in progression-free survival. Now that comes with a cost. About half of the patients required a dose reduction after an interruption, but the quality of life was maintained, and because of the dosing flexibility, again, 600, 500, 400, 300 twice daily, more than 70% of the patients could be maintained on 80% of the dose, which was 500 or 600. What's next? Next is ATHENA-COMBO. So in this ATHENA-MONO arm, the rucaparib was the experimental arm, but in ATHENA-COMBO, which is a fully powered independent but related study, now the rucaparib is the control arm. The experimental arm now randomized 1:1, 400 patients in each arm, will be rucaparib/nivolumab. You recall that JAVELIN 100 was negative adding avelumab to frontline chemotherapy. You'll recall that IMAGINE 50 was negative adding atezolizumab to bevacizumab, but now this is maintenance in PARP plus IO. So stay tuned. We hope to have the results to ATHENA-COMBO potentially next year against its event-driven analysis. It's my pleasure to share these data with you that were also published simultaneously in the Journal of Clinical Oncology on June 6, 2022.

Related Videos

Pancreatic Cancer

Pamela L. Kunz, MD, on Pancreatic Neuroendocrine Tumors: A Final Analysis of Temozolomide or Temozolomide Plus Capecitabine

Pamela L. Kunz, MD, of the Yale University School of Medicine, discusses new findings from the ECOG-ACRIN E2211 trial, which showed the longest progression-free survival and highest response rates with temozolomide plus capecitabine reported to date for patients with pancreatic neuroendocrine tumors. The presence of a deficiency of MGMT, the drug-resistance gene, was associated with greater odds of an objective response (Abstract 4004).

Gynecologic Cancers

Ursula A. Matulonis, MD, and Nicoletta Colombo, MD, on Ovarian Cancer: Overall Survival Data on Relacorilant Plus Nab-Paclitaxel

Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, and Nicoletta Colombo, MD, of the University of Milan and the European Institute of Oncology, discuss phase II results on the overall survival benefit of intermittent relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel, compared with nab-paclitaxel alone in patients with recurrent platinum-resistant ovarian cancer. A phase III trial comparing intermittent relacorilant plus nab-paclitaxel with investigator’s choice of chemotherapy in primary platinum-refractory disease is ongoing (Abstract LBA5503).

Neuroendocrine Tumors

Mairéad G. McNamara, PhD, MBBCh, on Neuroendocrine Carcinoma: Findings on Liposomal Irinotecan Plus Fluorouracil and Folinic Acid or Docetaxel

Mairéad G. McNamara, PhD, MBBCh, of The Christie NHS Foundation Trust, discusses phase II findings of the NET-02 trial, which explored an unmet need in the second-line treatment of patients with progressive, poorly differentiated extrapulmonary neuroendocrine carcinoma. In the trial, the combination of liposomal irinotecan, fluorouracil, and folinic acid, but not docetaxel, met the primary endpoint of 6-month progression-free survival rate (Abstract 4005).

Breast Cancer

Etienne Brain, MD, PhD, on Breast Cancer: Adjuvant Endocrine Therapy With or Without Chemotherapy in Older Patients

Etienne Brain, MD, PhD, of the Institut Curie, discusses phase III findings from the Unicancer ASTER 70s trial, in which patients aged 70 or older with estrogen receptor–positive, HER2-negative breast cancer and a high genomic grade index received adjuvant endocrine therapy with or without chemotherapy. The data did not find a statistically significant overall survival benefit with this treatment after surgery (Abstract 500).

Gynecologic Cancers
Immunotherapy

Ursula A. Matulonis, MD, and Ignace Vergote, MD, PhD, on Cervical Cancer: Interim Results on Tisotumab Vedotin-tftv Plus Pembrolizumab

Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, and Ignace Vergote, MD, PhD, of Belgium’s University Hospitals Leuven, discuss interim safety and efficacy results from a third dose-expansion cohort evaluating first-line tisotumab vedotin-tftv plus pembrolizumab in patients with recurrent or metastatic cervical cancer. Data on the combination showed durable antitumor activity with a manageable safety profile (Abstract 5507).

Advertisement

Advertisement




Advertisement